Aerovate Therapeutics Inc
AVTE
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.5B
Close$
$1.17
56.5% downside
Current Fair Value
56.5% downsideOvervalued by 56.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.50 Billion |
|---|---|
| Enterprise Value | $1.40 Billion |
| Dividend Yield | $2.40 (-) |
| Earnings per Share | $-3193.3 |
| Beta | 0.95 |
| Outstanding Shares | 61,050,775 |
Return
| Return on Equity | -42.94% |
|---|---|
| Return on Assets | -40.01% |
| Return on Invested Capital | -42.44% |
Valuation & Multiples
| P/E Ratio | -9.69 |
|---|---|
| PEG | -13.18 |
| Price to Sales | - |
| Price to Book Ratio | 0.38 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.47 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 10, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Jade Biosciences, Inc.
50 employees
CEO: Tom Frohlich Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) ...